« Back
Home /
Ribociclib succinate hydrate

Ribociclib succinate hydrate

€74.00

Excl. VAT

Item no.	HY-15777C-10mM
Manufacturer	MedChem Express
CASRN	1374639-79-8
Amount	10 mM/1 mL
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Brain Cancer Nervous System Cancer
Type	Inhibitors
Purity	99.96
Formula	C23H30N8O.C4H6O4.xH2O
Citations	Nat Commun. 2021 Aug 25;12(1):5112. Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):4001-4011. Biomed Chromatogr. 2020 Mar;34(3):e4783. Biomed Pharmacother. 2019 Feb 18;112:108602. Biomed Res Int. 2020 Jun 11;2020:9525207. Breast Cancer Res. 2019 Dec 26;21(1):150. Cancer Discov. 2023 Dec 4. Cancer Res. 2019 Oct 15;79(20):5245-5259. Cancers (Basel). 2022, 14(22), 5481 Cancers. 2020 Jun 16;12(6):1596. Cell Chem Biol. 2019 Aug 15;26(8):1067-1080.e8. Cell Death Dis. 2020 Sep 15;11(9):754. Cell Rep Med. 2023 Sep 12;101200. Cell Rep. 2017 Oct 31;21(5):1386-1398. Cell Rep. 2020 Aug 4;32(5):107995. Cell. 2023 Jun 8;186(12):2628-2643.e21. Clin Cancer Res. 2015 Nov 1;21(21):4947-59. Department of Biochemistry. 2020 Oct. Eur J Cancer. 2018 Oct;102:10-22. Eur J Drug Metab Pharmacokinet. 2021 Jul 18;1-11. Front Oncol. 2022 Apr 8;12:819003. Fundam Clin Pharmacol. 2021 Feb 1. Harvard Medical School LINCS LIBRARY Int J Biol Sci. 2019 Jan 1;15(3):522-532. J Chromatogr B. 2020 Jun 15;1147:122142. J Infect Dis. 2018 Nov 22;218(suppl_5):S365-S387. J Pharmaceut Biomed. 2021, 113933. J Transl Med. 2022 May 13;20(1):217. J Virol. 2023 May 23;e0037023. Leuk Res. September 2022, 106920. Mil Med Res. 2022 Dec 19;9(1):71. Mol Cancer Ther. 2018 May;17(5):897-907. Mol Cell. 2017 Oct 19;68(2):336-349.e6. Mol Oncol. 2017 Aug;11(8):1035-1049. Nat Commun. 2021 Sep 10;12(1):5386. Nat Commun. 2022 Aug 10;13(1):4689. Nat Commun. 2019 Jun 28;10(1):2860. Nature Cancer. 2021 Apr;2(4):429-443. Naunyn Schmiedebergs Arch Pharmacol. 2023 Feb 4. NPJ Precis Oncol. 2021 Mar 19;5(1):20. Patent. US20220354911A1. PLoS One. 2022 Dec 22;17(12):e0279522. Research Square Print. November 7th, 2022 RSC Adv. 2020, 10(38):22668-22683. Sci Adv. 2022 Dec 23;8(51):eadc8911. Sci Rep. 2021 Mar 8;11(1):5374. Sci Rep. 2022 Jul 20;12(1):12420. Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. bioRxiv. 2023 Sep 16. Clin Cancer Res. 2015 Nov 1;21(21):4947-59. JCI Insight. 2021 Dec 21;e154402. Cell Chem Biol. 2018 Feb 15;25(2):135-142.e5. [1]VanArsdale T, et al. Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment. Clin Cancer Res. 2015 Jul 1;21(13):2905-10. [2]Rader J, et al. Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma. Clin Cancer Res. 2013 Nov 15;19(22):6173-82.
Smiles	O=C(N(C)C)C(N1C2CCCC2)=CC(C1=N3)=CN=C3NC(N=C4)=CC=C4N5CCNCC5.OC(CCC(O)=O)=O.[x H2O]
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	LEE011 (succinate hydrate)
Available
Product Description	Ribociclib succinate hydrate (LEE011 succinate hydrate) is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and is over 1, 000-fold less potent against the cyclin B/CDK1 complex.
StorageTemperature	4°C (Powder, sealed storage, away from moisture)
Shipping	Room Temperature
Manufacturers Applications	Cancer-Kinase/protease
Molecular Weight	N/A
Clinical Information	Launched
Solubility	DMSO : ≥ 20 mg/mL\|H2O : 4 mg/mL (ultrasonic)
Isoform	CDK4; CDK6
Pathway	Cell Cycle/DNA Damage
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-15777C-10mM-safety-datasheet.pdf